CD BioSciences Announces Advanced Environmental Microbiology Testing Services for Environmental Protection
CD BioSciences, a bio-sustainable solutions company, is proud to announce its environmental microbiology testing services, a step further in its commitment to eco-friendly innovations and sustainability.
In its cutting-edge biotechnology facility, CD BioSciences is listening to customer needs for more sustainable and environmentally friendly practices. The company is answering with a new line of environmental microbiology testing services. This is a part of a larger goal to help improve biodiversity and ecological well-being in agriculture, industry, and urban development, and the highly customized and scientific testing services are designed for solutions that help advance eco-conscious practices and protect the natural world.
The environmental microbiology testing services utilize the latest in microbiological analysis methods and techniques to track and manage microorganisms in various settings. In addition to playing a part in the overall well-being of the world, this service is critical to the health of agricultural land and growth, clean water, and pollutant-free air. Reliable and precise microbiology analysis and testing are key to ensuring thriving soil, safe and clean water supplies, and improving air quality, all a part of a sustainable environment.
CD BioSciences also offers bioenvironmental microorganism products. These new products are an innovative line of environmentally friendly, non-invasive solutions that use naturally occurring microorganisms to improve and fortify the environment and help nature protect itself. These products are designed to boost the microorganisms and activity that help to improve soil, break down pollutants, and encourage the cycles of nutrients that all healthy ecosystems rely on. By using these biological products and solutions, industries and others can help meet environmental standards and targets, increase their sustainability performance, and decrease their environmental footprint.
In addition to these new products, CD BioSciences also assists with material biodegradation studies and testing for industry. Biodegradation analysis measures the effect of microorganisms on materials in the environment, including their rate of decay, and helps to determine the long-term effects of these substances and processes on the environment. It's a critical service for determining material and process alternatives for companies seeking to use and produce more sustainable products and processes with less waste.
In conclusion, CD BioSciences is at the forefront of improving the health of the planet, with new microbiology testing services and environmentally friendly bioenvironmental microorganism products. With an eye always on the future and a focus on the highest quality products and services possible.
About CD BioSciences
CD BioSciences is a leading biotechnology company based in New York, dedicated to the ideals of innovation and sustainability. The company provides a range of eco-friendly products and services to industries worldwide in the agriculture, environmental, and biochemical fields, and offers a complete package of products and solutions backed by top-notch technical support.
Media Contact
Company Name: CD BioSciences
Contact Person: Michelle Moser
Email: Send Email
Country: United States
Website: https://www.sustainable-bio.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: CD BioSciences Announces Advanced Environmental Microbiology Testing Services for Environmental Protection
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
16 minutes ago
- New York Times
Veterans Affairs Dept. Scales Back Plans for Vast Job Cuts
The Department of Veterans Affairs has scaled back its effort to reduce its work force by more than 80,000 people, saying on Monday that it intended to cut nearly 30,000 jobs by the end of September instead. The department effectively abandoned its previous plan to fire tens of thousands of workers as part of President Trump's wide-reaching plan to slash the federal bureaucracy. The new target, outlined in a department news release, would slash a work force that numbered 484,000 earlier this year to about 455,000. Nearly 17,000 employees have already left. Instead of firing workers, the rest of the cuts would be made by offering early retirement or severance payments, along with what the department described as 'normal attrition' — the small percentage of employees who quit or move to other jobs every year. 'A departmentwide R.I.F. is off the table,' said Doug Collins, the veterans affairs secretary, referring to a reduction in force, the formal process to initiate mass layoffs in the agency. 'As a result of our efforts, V.A. is headed in the right direction — both in terms of staff levels and customer service,' he said. The department, which provides health care for military veterans, had previously insisted that job cuts would not affect services, and said again on Monday that it had 'multiple safeguards in place' to prevent disruptions. A law signed by President Joseph R. Biden Jr. had significantly expanded the veterans benefits system and set off a record-breaking hiring spree at the department. The department said on Monday that it had continued to cut a backlog of benefits claims after a spike during the Biden administration. In addition to its primary mission of providing care to veterans and serving as the nation's backup health care system, the department also oversees some medical research and manages veterans benefits programs — like pensions, banking, home loans, insurance, job training and funding for college degrees.
Yahoo
17 minutes ago
- Yahoo
ServiceNow Trades 16% Below 52-Week High: Buy, Sell or Hold the Stock?
ServiceNow NOW shares closed at $1,011.89 on Tuesday (July 2), roughly 15.5% below the 52-week high of $1,198.09 it hit on Jan. 28, 2025. NOW shares have dropped 4.5% year to date (YTD), underperforming the Zacks Computer and Technology sector's return of 5.7% but outperforming the Zacks Computers – IT Services industry's drop of 6.3%.NOW shares have suffered from a worsening macroeconomic environment following U.S. President Donald Trump's decision to levy tariffs on trading partners, including China and Mexico. The company's federal business is expected to suffer from DOGE-related issues. ServiceNow expects unfavorable forex impacts of $175 million for 2025 and back-end loaded federal business is expected to hurt the growth strategy to accelerate the adoption of its Agentic AI by foregoing immediate revenues is expected to affect the subscription revenue growth rate in 2025. Image Source: Zacks Investment Research However, since reporting first-quarter 2025 results on April 23, ServiceNow shares have jumped 24.5%. NOW has been benefiting from the rising adoption of its workflows by enterprises undergoing digital transformation. The company's expanding portfolio, accretive acquisitions and a rich partner base are the key ServiceNow's stock is displaying a bullish trend as it is trading above both 200-day and 50-day moving averages. Image Source: Zacks Investment Research So, what should investors do with the NOW stock? Let us dig deeper to find out. NOW's expanding portfolio has been a major driver. In May 2025, ServiceNow introduced its Core Business Suite, an AI-powered solution designed to streamline and transform core business operations, including HR, finance, procurement, facilities and legal, by unifying workflows and automating processes across departments to improve efficiency, reduce time to value and enhance employee announced the launch of AI agents in its Security and Risk solutions, transforming enterprise security by enabling self-defending systems, improving response times, and enhancing risk management in collaboration with Microsoft MSFT and Cisco. Expanding its portfolio in May 2025, NOW announced advancements in autonomous IT, introducing agentic AI capabilities on the ServiceNow AI Platform to drive zero outages, zero downtime and zero service desk enterprise workflow automation suite has been gaining traction as enterprises increasingly adopt digital tools to streamline operations across departments. Through the Now platform, ServiceNow supports diverse workflows, ranging from IT service management and customer service to HR, employee experience and app have also played an important role in expanding NOW's portfolio. In April 2025, ServiceNow announced the acquisition of a company specializing in AI-powered and Configure, Price, Quote solutions. This move is set to bolster ServiceNow's CRM offerings, particularly in sales and order management, by integrating advanced AI expanding platform is driving enterprise adoption. In the first quarter of 2025, the company reached 508 customers, generating more than $5 million in ACV, representing 20% year-over-year growth. Expanding customer base is driving subscription revenues, which hit $3.01 billion in the first quarter of 2025, reflecting year-over-year growth of 20% in constant currency. A rich partner base that includes the likes of Alphabet, Amazon AMZN, Microsoft and NVIDIA NVDA is noteworthy. In May 2025, NOW partnered with Amazon's cloud computing arm, Amazon Web Services, to launch a bi-directional data integration solution, enabling enterprises to unify data and trigger AI-powered workflows by connecting ServiceNow with Amazon and NOW collaborated to launch AI agents for the telecom industry. The AI agents were built with NVIDIA AI Enterprise software and the AI platform NVIDIA DGX Cloud. ServiceNow has expanded its partnership with NVIDIA to enhance agentic AI by integrating NVIDIA Llama Nemotron reasoning models and AI agent evaluation tools into the ServiceNow Platform for optimized business transformation. The Zacks Consensus Estimate for 2025 earnings is pegged at $16.54 per share, up by a penny over the past 30 days, indicating an 18.82% increase from the 2024 reported figure. ServiceNow, Inc. price-consensus-chart | ServiceNow, Inc. Quote The consensus mark for second-quarter 2025 earnings is pegged at $3.54 per share, up by a penny over the past 30 days, suggesting year-over-year growth of 13.1%. NOW stock is overvalued, as suggested by the Value Score of terms of the forward 12-month Price/Sales, NOW is trading at 14.75X, higher than the broader sector's 6.51X. Image Source: Zacks Investment Research ServiceNow's expanding portfolio and strong partner base are expected to drive its clientele, boosting subscription revenues. However, unfavorable forex amid a challenging macroeconomic environment is concerning. NOW's stretched valuation makes the stock unattractive for value currently has a Zacks Rank #3 (Hold), which implies that investors should stay away from the stock for the time can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report ServiceNow, Inc. (NOW) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
17 minutes ago
- Yahoo
Apple is still trying to overturn the ban on the Apple Watch blood oxygen sensor
Apple is making another attempt to appeal the trade ban that forced it to remove the blood oxygen sensor from its smartwatches, Reuters reports. The company was forced to remove the feature in 2024, following a decision from the International Trade Commission (ITC) in 2023 that banned sales of the Apple Watch for violating health tech startup Masimo's patents. The US Court of Appeals for the Federal Circuit heard new arguments from Apple and Masimo's lawyers on Monday over the legality of the original ITC ban. Apple's argument is that the fact Masimo was developing its own smartwatch when Apple released the Apple Watch Series 6 in 2020 — the first of the company's wearables with a blood oxygen sensor — shouldn't be enough to justify the ban. Masimo disagrees. The appeals court has heard the company's arguments before, and even briefly paused the trade ban in December 2023 while the ITC considered Apple's request for a longer pause. Ultimately, the ITC ruled in Masimo's favor and denied Apple's request. Apple removed the blood oxygen sensor in 2024 so it could restart sales of the Apple Watch Series 9 and Apple Watch Ultra 2 in the US. The companies' fight goes beyond just the blood oxygen sensor — Masimo's smartwatches were, ironically, found to infringe on Apple patents — but clearly Apple is hung up on the feature. The company's blood oxygen sensor was never as accurate as the pulse oximeters used in a doctor's office, but it was part of a fairly comprehensive suite of heart health features on the smartwatch. It's entirely possible Apple wants to reintroduce it in its watches as part of an even more ambitious health feature down the road.
